Kelun Pharma of China Sells Unknown Cancer Drug To Merck For $1.4B

U.S. pharma group Merck’s already impressive immuno-oncology pipeline has been beefed up through a deal with Sichuan Kelun Pharmaceutical of China to add an undisclosed cancer-treating drug to its slate. Though details are scant, it is known that Merck owes $47 million in upfront payments for licensing rights outside Hong Kong, China, Taiwan, and Macao...